# Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

> **NCT01315795** · PHASE2,PHASE3 · COMPLETED · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 59 (actual)

## Conditions studied

- Polycystic Liver Disease

## Interventions

- **DRUG:** Lanreotide Autogel 90 mg and 120 mg

## Key facts

- **NCT ID:** NCT01315795
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2014-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01315795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01315795, "Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01315795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*